Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company, based in Schlieren-Zurich, Switzerland, that develops a new class of therapies known as DARPins, closed its initial public offering and listing on the SIX Swiss Exchange AG. 4,400,000 shares of Molecular Partners AG were placed at CHF 22.40 per share, leading to a market capitalization of Molecular Partners AG of approximately CHF 485 million on a fully-diluted basis (prior to exercise of the over-allotment option granted to the underwriting banks).

Homburger acted as lead legal counsel to Molecular Partners AG. The team was led by partner Dieter Gericke (Corporate | M&A) and included partners Peter Riedweg (Tax), Andri Hess (IP | IT), and Frank Gerhard (Corporate | M&A), counsels Lee Saladino (Financial Services) and Peter Müller (Tax), associates Sergio Bortolani, Karin Mattle and Matthias Maurer (all Corporate | M&A), associate Richard Stäuber (IP | IT) and junior associates Désirée Klingler, Kevin Hubacher and Gabriel Wildberger (all Corporate | M&A).

J.P. Morgan has been acting as the Sole Global Coordinator and Joint Bookrunner and UBS Investment Bank as Joint Bookrunner. Cowen and Company and Bank am Bellevue have been acting as Co-Managers in connection with the IPO.